17:38 IST
NSE
Product Launch
Lupin Product Launch
Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.
Lupin Ltd
Lupin Ltd news stories on ALFA NewsRead the news →- Share price
- ₹2,029.30
- Market cap
- ₹92,798 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 16.8×Sector 47.4×
- Promoter holding
- 46.85%-0.01% QoQ
- FII holding
- 22.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Regulatory Approval 10Other Announcement 9Employee Stock Options 7Earnings Call 5Product Launch 4Financial Results 4Merger & Restructuring 3Business Update 3Annual General Meeting 3Partnership 2Management Change 2Results Update 1Legal & Regulatory 1Dividend 1Board Meeting Outcome 1Board Meeting Date 1
Time
4 announcements with these filters
11:14 IST
NSE
Product Launch
Lupin Product Launch
Lupin Limited has launched Sugammadex Injection in the United States following U.S. FDA approval. The product is a bioequivalent to Merck's Bridion® for reversing neuromuscular blockade.
09:12 IST
BSE
Product Launch
Lupin Product Launch
Lupin Limited has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. This follows approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA). The product is a generic version of Xigduo XR, expanding Lupin's anti-diabetic portfolio in the U.S. market.
19:49 IST
NSE
Product Launch
Lupin Product Launch
Lupin Limited has launched Dapagliflozin Tablets (5 mg and 10 mg) in the United States. The product is a bioequivalent generic version of Farxiga®, following approval from the U.S. FDA. This launch expands Lupin's anti-diabetic portfolio in the U.S. market, leveraging its strong position across multiple therapy areas.